Biosimilars
-
Uptake of Biosimilars Remains Low Among People with Employer-Sponsored Insurance
Read more: Uptake of Biosimilars Remains Low Among People with Employer-Sponsored InsuranceBiologic drugs represent advances in medical research and treatment but are a major driver of drug spending in the United States. Spending on biologics increased by 50% between 2014 and 2018 in the U.S. even though just 2% of Americans used them. Biosimilars, clinically equivalent, lower-cost versions of original biologic drugs, analogous to generic versions…
-
Biosimilar Savings among People with Employer-Sponsored Insurance Not Keeping Pace with Savings in Medicare
Read more: Biosimilar Savings among People with Employer-Sponsored Insurance Not Keeping Pace with Savings in MedicareBiologic drugs include a range of life-saving medications to treat cancer, diabetes, rheumatoid arthritis, retinal diseases, and many other conditions. Unlike “small molecule” drugs (e.g., statins), which can generally be taken at home, biologics are typically infusions or injections which require administration by a physician or other clinician in a hospital or physician’s office. While just…